Two Concerta Generics Lose Therapeutic Equivalency Rating
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA downgrades Mallinckrodt and Kudco’s methylphenidate generics from AB- to BX-rated. An influx of patient complaints about lack of efficacy spurred an investigation of the products and subsequent revision of the agency’s draft bioequivalence guidelines for the ADHD drug.
You may also be interested in...
FDA Asks For Input On Therapeutic Equivalence
The FDA wants to know if the second letter in its product equivalence ratings system is helpful and whether changes could make the information more user-friendly.
'Orange Book' Changes? US FDA Soliciting Comments On TE Codes
The agency wants to know if the second letter in the product equivalence ratings system is helpful and whether changes could make the information more user-friendly.
FDA Pushing Forward With Withdrawal Of Two Concerta Generics
Mallinckrodt and Kremers seem prepared to fight formal notice, which comes almost two years after FDA found their methylphenidate generics failed to demonstrate bioequivalence to the Janssen's brand drug.